Racial and socioeconomic disparities in the selection of prostate brachytherapy

Journal of Contemporary Brachytherapy

Volumn 5, Issue 3, 2013, Pages 139-143

  Schreiber, David ^a,b   Chen, Shan Chin ^a,b   Rineer, Justin ^c   Weiss, Jeffrey ^a,b   Rotman, Marvin ^a,b   Schwartz, David ^a,b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

Brachytherapy; Prostate cancer; Racial disparities; Radiation; Socioeconomic disparities

Indexed keywords

AFRICAN AMERICAN; ARTICLE; BRACHYTHERAPY; COST OF LIVING; HEALTH DISPARITY; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RACE; SOCIAL STATUS;

EID: 84885787528     PISSN: 1689832X     EISSN: None     Source Type: Journal    
DOI: 10.5114/jcb.2013.37563     Document Type: Article

References (28)

1. http://www.cancer.org/cancer/prostatecancer/detailedguide/ prostate-cancer-key-statistics [accessed 7/9/13].
2. Chornokur G, Dalton K, Borysova ME et al. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 2011; 71: 985-997.
3. Du XL, Fang S, Coker AL et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer 2006; 106: 1276-1285.
4. Cheng I, Witte JS, McClure LA et al. Socioeconomic status and prostate cancer incidence and mortality rates among the diverse population of California. Cancer Causes Control 2009; 20: 1431-1440.
5. Woods LM, Rachet B, Colema MP. Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol 2006; 17: 5-19.
6. Terakedis BE, Rossi PJ, Liauw SL et al. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age. Am J Clin Oncol 2010; 33: 619-623.
7. Zelefsky MJ, Moughan J, Owen J et al. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 patterns of care survey for prostate cancer. Int J Radiat Oncol Biol Phys 2004; 59: 1053-1061.
8. Guedea F, Venselaar J, Hoskin P et al. Patterns of Care for Brachytherapy in Europe: Updated Results. Radiother Oncol 2010; 97: 514-520.
9. Terakedis BE, Rossi PJ, Liauw SL et al. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age. Am J Clin Oncol 2010; 33: 619-623.
10. Hamilton AS, Albertsen PC, Johnson TK et al. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int 2011; 107: 576-584.
11. Underwood W, De Monner S, Ubel P et al. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol 2004; 171: 1504-1507.
12. Rose AJ, Backus BM, Gershman ST et al. Predictors of aggressive therapy for nonmetastatic prostate carcinoma in Massachusetts from 1998 to 2002. Med Care 2007; 45: 440-447.
13. Hoffman RM, Harlan LC, Klabunde CN et al. Racial differences in initial treatment for clinically localized prostate cancer. J Gen Internal Med 2003; 18: 245-253.
14. Hayes J, McMahon P, Pearson SD. Institute For Clinical and Economic Review; Final Appraisal Document. Brachytherapy and proton beamtherapy for treatment of clinically-localized, low risk prostate cancer. Institute for Clinical and Economic Review; available at: http://www.icerreview.org/index.php? option-com-content&task-view&id-18&Itemid-39 (accessed 06/11/2013).
15. Shah C, Lanni TB, Ghilezan MI et al. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Brachytherapy 2012; 11: 441-445.
16. Hoskin PJ, Motohashi K, Bownes P, et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomized phase three trial. Radiother Oncol 2007; 84: 114-120.
17. Pieters BR, de Back DZ, Koning CC et al. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol 2009; 93: 168-173.
18. Grimm P, Billiet I, Bostwick D et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012; 109: 22-29.
19. Prestidge BR, Prete JJ, Buchholz TA et al. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 1998; 40: 461-465.
20. Buyyounouski MK, Davis BJ, Prestidge BR et al. A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 Update. Brachytherapy 2012; 11: 299-305.
21. Merrick GS, Lief JH, Grimm P et al. The effect of pro-quora case volume on post-implant dosimetry. Int J Radiat Oncol Biol Phys 2011; 81: 727-734.
22. Lee WR, Deguzman AF, Bare RL et al. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: Evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys 2000; 46: 83-88.
23. Bladou F, Salem N, Simonian-Sauve M et al. Permanent iodine 125 implant brachytherapy in localized prostate cancer: Results of the first 4 years of experience. Prog Urol 2004; 14: 345-352.
24. Hoinkis C, Hakenberg OW, Lehmann D et al. Evaluation of dose-volume histograms after prostate seed implantation: 4-year experience. Strahlenther Onkol 2004; 180: 550-556.
25. Bice WS Jr., Prestidge BR, Grimm PD et al. Centralized multi-institutional postimplant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998; 41: 921-927.
26. Steenland K, Goodman M, Liff J et al. The effect of race and rural residence on prostate cancer treatment choice in rural Georgia. Urology 2011; 77: 581-587.
27. Denberg TD, Kim FJ, Flanigan RC et al. The influence of patient race and social vulnerability on urologist treatment recommendations in localized prostate carcinoma. Med Care 2006; 44: 1137-41.
28. Virnig BA, Warren JL, Cooper GS et al. Studying radiation therapy using SEER-Medicare-linked data. Med Care 2002; 40 (8 Suppl IV): 49-54.